Archives
How mRNA–LNP Quality Shapes Translation
2026-11-10
mRNA–lipid nanoparticles succeed when molecular design, particle attributes, physiological behavior, and manufacturing control remain causally aligned. The strongest evidence supports a systems-level interpretation: ionizable lipid chemistry can balance delivery and tolerability, but no single critical quality attribute independently predicts clinical performance.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-10
A 2025 study reports that targeted placement of a reporter gene under the endogenous CSN2 regulatory context produced 15–20 g/L tdTomato in milk from two homozygous rabbits. The result supports a strong locus-and-promoter effect hypothesis, but it does not yet establish equivalent performance for therapeutic proteins, population-wide reproducibility, or manufacturing readiness.
HEPES and the Limits of Rabbit Pharming Evidence
2026-11-09
A targeted rabbit expression study reported unusually high milk concentrations of a fluorescent reporter, but its findings support a narrow promoter-and-locus proof of concept rather than evidence for HEPES, intracellular pH modulation, or therapeutic-protein production in general.
What CMC Determines in mRNA–LNP Translation
2026-11-09
A literature-focused analysis of how lipid chemistry, particle attributes, manufacturing strategy, analytical controls, and physiological stability shape the translation of mRNA lipid nanoparticles from proof of concept to clinical products.
A High-Yield Rabbit Pharming Strategy, Examined
2026-11-08
A literature-focused analysis of a 2025 study that used targeted insertion at the rabbit CSN2 locus to drive tdTomato expression in milk, reporting 15–20 g/L in two homozygous females while highlighting the limits of reporter-based and cross-study comparisons.
Targeted Rabbit Pharming and Milk Yield
2026-11-07
A 2025 study tested whether targeted insertion at the endogenous CSN2 milk-protein locus could improve recombinant protein output in rabbits. Its reported 15–20 g/L tdTomato concentration is promising, but the evidence remains a reporter-based demonstration rather than a controlled validation of therapeutic protein manufacturing.
When Context Changes What a Yield Result Means
2026-11-06
A reported 15–20 g/L milk concentration is meaningful only within the study’s genetic model, reporter choice, comparator, and readout. The rabbit pharming study supports a targeted CSN2-locus proof of concept, while offering no basis for attributing the result to HEPES, intracellular pH modulation, or lysosomal biology.
Targeted Promoters and High-Yield Rabbit Pharming
2026-11-06
A literature-focused analysis of a 2025 study that used targeted insertion at the rabbit CSN2 locus to drive tdTomato expression in milk. The reported 15–20 g/L concentration in two homozygous females is striking, but the evidence remains a proof of concept because it concerns a reporter protein, a small animal cohort, and historical rather than contemporaneous comparisons.
How CSN2 Targeting Raised Rabbit Milk Yield
2026-11-05
A 2025 study examined whether placing a reporter gene at the endogenous rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenic pharming. The reported 15–20 g/L tdTomato yield in two homozygous animals is substantial, but its interpretation remains bounded by the reporter-only design, small animal-level evidence, and cross-study comparisons.
How CMC Shapes mRNA-LNP Translation
2026-11-05
A mechanistic editorial on how lipid chemistry, nanoparticle attributes, manufacturing comparability and orthogonal analytics shape the translation of mRNA lipid nanoparticles.
What High-Yield Rabbit Pharming Shows
2026-11-04
A targeted rabbit milk-expression study reported recombinant-protein concentrations of 15–20 g/L, but its strongest evidence is a proof-of-concept rather than a definitive demonstration of general superiority. The result supports the importance of genomic context while leaving questions about reproducibility, protein-specific performance, native milk biology and product quality unresolved.
How LNP Chemistry Shapes mRNA Translation
2026-11-04
A mechanistic editorial examines how lipid charge state, nanoparticle quality attributes, physiological stability, and manufacturing comparability influence mRNA delivery. It distinguishes what a 2026 review establishes from what remains uncertain, especially when downstream protein expression cannot identify the upstream delivery step responsible for an observed effect.
What CMC Means for mRNA-LNP Translation
2026-11-03
mRNA–lipid nanoparticle translation depends on more than delivery potency. The central challenge is connecting lipid chemistry, particle attributes, manufacturing history, physiological stability and clinical performance through a defensible chemistry, manufacturing and controls strategy.
HEPES and the Mechanism of Targeted Rabbit Pharming
2026-11-03
A 2025 rabbit study linked insertion of a fluorescent reporter into the endogenous CSN2 regulatory environment with unusually high milk expression. The result supports a locus- and promoter-focused pharming concept, but it does not establish a role for HEPES, intracellular pH modulation, or equivalent performance for therapeutic proteins.
How a CSN2 Knock-In Raised Rabbit Milk Yield
2026-11-02
A 2025 study tested whether placing a reporter gene under the endogenous rabbit CSN2 milk-protein regulatory system could overcome the variable expression associated with conventional transgenic lines. The resulting heritable line produced 15–20 g/L tdTomato in milk from two homozygous females, an encouraging but still preliminary result whose applicability to therapeutic proteins remains untested.